SRSF4: A Potential Drug Target for Cancer (G6429)

Target Name: SRSF4

NCBI ID: G6429

SRSF4

SRSF4: A Potential Drug Target for Cancer

Splicing factor, arginine/serine-rich 4 (SRSF4) is a protein that plays a critical role in the regulation of gene expression in cancer cells. It is a key factor in the process of splicing, which is the process by which the DNA code is turned into RNA and ultimately translated into proteins. SRSF4 is located in the nucleus and is known to interact with other proteins, including the transcription factor, p53. SRSF4 has been shown to be a potential drug target and biomarker in cancer.

SRSF4 is a 21-kDa protein that is composed of 205 amino acids. It is found in all cell types and is expressed in high levels in cancer cells. SRSF4 is a key regulator of gene expression and has been shown to play a role in the development and progression of many types of cancer.

One of the functions of SRSF4 is to promote the splicing of RNA. During splicing, the SRSF4 protein helps to recruit the RNA polymerase to the start of the coding region of the pre-mRNA and then guides the RNA polymerase to make the necessary cuts in the pre-mRNA to remove the introns and create a sense RNA. This process is essential for the production of functional proteins from the DNA code.

SRSF4 has also been shown to play a role in the regulation of gene expression in cancer cells. Many studies have shown that high levels of SRSF4 are associated with the development and progression of many types of cancer, including breast, ovarian, and prostate cancers.

In addition to its role in gene expression, SRSF4 has also been shown to play a role in the regulation of cellular processes. For example, SRSF4 has been shown to be involved in the regulation of cell adhesion, cell migration, and the association of the immune system with cancer.

SRSF4 is also a potential biomarker for cancer. Because it is a key regulator of gene expression and has been shown to play a role in the development and progression of cancer, SRSF4 has the potential to be used as a biomarker for cancer. This can be used to identify patients who are at risk for cancer and to monitor the effectiveness of cancer treatments.

SRSF4 is also a potential drug target for cancer. Because it plays a role in the regulation of gene expression and has been shown to be involved in the development and progression of cancer, SRSF4 is a potential target for cancer therapies. This can include drugs that target SRSF4 directly or drugs that inhibit its activity.

In conclusion, SRSF4 is a protein that plays a critical role in the regulation of gene expression in cancer cells. It is a key factor in the process of splicing and has been shown to play a role in the development and progression of many types of cancer. In addition to its role in gene expression, SRSF4 has also been shown to play a role in the regulation of cellular processes and has the potential to be used as a biomarker for cancer. SRSF4 is also a potential drug target for cancer and has the potential to be used as a therapeutic agent. Further research is needed to fully understand the role of SRSF4 in cancer and to develop effective treatments.

Protein Name: Serine And Arginine Rich Splicing Factor 4

Functions: Plays a role in alternative splice site selection during pre-mRNA splicing. Represses the splicing of MAPT/Tau exon 10

The "SRSF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRSF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets